THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) —
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA.
The presentations will highlight positive results from the initial phase of Autonomix’s first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Details of the presentations are as follows:
Title:
Illuminating the Nervous System with Transvascular Precision-Guided Technology
Session: Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases
Presenter: Robert S. Schwartz, MD, FACC
Date and Time: Monday, October 27, at 7:30 AM PDT
Location: Innovation Theater, Hall E, Exhibition Level, Moscone North
Title: Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation
Session: Hypertension and Renal (and other organ system) Denervation – 2
Presenter: Robert S. Schwartz, MD, FACC
Date and Time: Monday, October 27, at 9:00 AM PDT
Location: Station 5, Halls B-C, Exhibition Level, Moscone South
For more information about TCT 2025, visit the conference website here.
About TCT 2025
TCT 2025 is a comprehensive 4-day educational conference, sponsored by the Cardiovascular Research Foundation (CRF), taking place October 25-28, 2025, at the Moscone Center in San Francisco, California. Founded by Dr. Martin B. Leon, the Transcatheter Cardiovascular Therapeutics® (TCT®) conference is the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®) and the world’s foremost educational forum specializing in interventional cardiovascular medicine. Debuting as a small gathering of 150 in 1988, TCT® now attracts thousands of attendees from around the world. Every year, TCT® features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
